MA43761A - 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj - Google Patents

6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj

Info

Publication number
MA43761A
MA43761A MA043761A MA43761A MA43761A MA 43761 A MA43761 A MA 43761A MA 043761 A MA043761 A MA 043761A MA 43761 A MA43761 A MA 43761A MA 43761 A MA43761 A MA 43761A
Authority
MA
Morocco
Prior art keywords
apj
dihydropyrimidine
carboxamides
oxo
inhibitors
Prior art date
Application number
MA043761A
Other languages
English (en)
Inventor
Donna M Bilder
Robert Paul Brigance
Heather Finlay
Wen Jiang
James A Johnson
R Michael Lawrence
Wei Meng
Michael C Myers
Monique Phillips
Zulan Pi
George O Tora
Xiaojun Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA43761A publication Critical patent/MA43761A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA043761A 2016-03-24 2017-03-23 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj MA43761A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662312780P 2016-03-24 2016-03-24

Publications (1)

Publication Number Publication Date
MA43761A true MA43761A (fr) 2021-05-05

Family

ID=58464691

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043761A MA43761A (fr) 2016-03-24 2017-03-23 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj

Country Status (22)

Country Link
US (2) US10106528B2 (fr)
EP (1) EP3433247B1 (fr)
JP (1) JP6716711B2 (fr)
KR (1) KR102433280B1 (fr)
CN (1) CN109195963B (fr)
AR (1) AR107973A1 (fr)
AU (1) AU2017238504B2 (fr)
BR (1) BR112018068341A2 (fr)
CA (1) CA3018346A1 (fr)
CL (1) CL2018002671A1 (fr)
CO (1) CO2018011105A2 (fr)
EA (1) EA037162B1 (fr)
ES (1) ES2895124T3 (fr)
IL (1) IL261904B (fr)
MA (1) MA43761A (fr)
MX (1) MX379088B (fr)
MY (1) MY189454A (fr)
SG (1) SG11201808163WA (fr)
TW (1) TWI744301B (fr)
UY (1) UY37169A (fr)
WO (1) WO2017165640A1 (fr)
ZA (1) ZA201806356B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59220B1 (sr) 2015-06-03 2019-10-31 Bristol Myers Squibb Co 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primenu u lečenju kardiovaskularnih poremećaja
SG10201908839QA (en) 2015-10-14 2019-10-30 Bristol Myers Squibb Co 2,4-dihydroxy-nicotinamides as apj agonists
KR102678264B1 (ko) 2015-12-04 2024-06-24 브리스톨-마이어스 스큅 컴퍼니 아펠린 수용체 효능제 및 사용 방법
JP6948322B2 (ja) 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン
JP6716711B2 (ja) * 2016-03-24 2020-07-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊアゴニストとしての６−ヒドロキシ−４−オキソ−１，４−ジヒドロピリミジン−５−カルボキシアミド
WO2017192485A1 (fr) 2016-05-03 2017-11-09 Amgen Inc. Composés triazole hétérocycliques utilisés en tant qu'agonistes du récepteur apj
KR102384668B1 (ko) * 2016-06-14 2022-04-07 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온
EP3468952B1 (fr) 2016-06-14 2020-11-25 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones utilisés en tant qu'agonistes du récepteur apj
CN110072850B (zh) 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018093579A1 (fr) 2016-11-16 2018-05-24 Amgen Inc. Composés phényle triazole en tant qu'agonistes du récepteur apj
EP3541805B1 (fr) 2016-11-16 2020-10-14 Amgen Inc. Triazoles substitués par hétéroaryle utilisés en tant qu'agonistes du récepteur apj
WO2018097944A1 (fr) 2016-11-16 2018-05-31 Amgen Inc. Composés de triazole furane utilisés en tant qu'agonistes du récepteur apj
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH602664A5 (en) * 1973-06-14 1978-07-31 Sandoz Ag 2-Tert. amino-alkylamino-pyrimidine derivs.
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
US5985884A (en) 1996-07-01 1999-11-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6943173B2 (en) 2000-07-18 2005-09-13 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
WO2003094839A2 (fr) 2002-05-09 2003-11-20 Cytokinetics, Inc. Composes, compositions et procedes
US20050234080A1 (en) 2002-05-23 2005-10-20 Coleman Paul J Mitotic kinesin inhibitors
JP2004339159A (ja) 2003-05-16 2004-12-02 Sankyo Co Ltd ４−オキソキノリン誘導体を含有する医薬組成物
EP1699777B1 (fr) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidylpeptidase
WO2005041888A2 (fr) 2003-11-03 2005-05-12 Cytokinetics, Inc. Composes, compositions et methodes
EP1697331A4 (fr) 2003-12-19 2010-08-04 Merck Sharp & Dohme Inhibiteurs de kinesines mitotiques
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007037543A1 (fr) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. Dérivé de biarylamide
WO2007064797A2 (fr) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
WO2007124397A2 (fr) 2006-04-21 2007-11-01 Trustees Of Boston University Substances viscoélastiques ioniques et sels viscoélastiques
EP2079707B1 (fr) 2006-10-10 2014-12-03 proionic GmbH & Co KG Procédé de mise en réaction de 2-carboxylates 1,3 hétéroaromatiques avec de l'eau
WO2008052861A2 (fr) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Procédé de production de carbonates 1,3-hétéroaromatiques exempts de 4-carboxylate
CL2008000065A1 (es) * 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
CA2676173A1 (fr) 2007-02-16 2008-08-28 Amgen Inc. Ketones heterocyclyles contenant de l'azote et leur utilisation comme inhibiteurs de c-met
WO2009129120A2 (fr) 2008-04-15 2009-10-22 Rfs Pharma, Llc Dérivés nucléosidiques destinés au traitement d’infections par un virus de la famille des caliciviridae, y compris d’infections par le norovirus
US20110253929A1 (en) 2008-12-22 2011-10-20 Basf Se Mixtures of hydrophobic and hydrophilic ionic liquids and use thereof in liquid ring compressors
CA2762680C (fr) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methylsulfanylpyrimidines utiles en tant qu'agents anti-inflammatoires, analgesiques, et anti-epileptiques
JP6075621B2 (ja) 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
JP5990262B2 (ja) 2011-05-31 2016-09-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ヒドリド−トリシアノ−ボラートアニオンを含む化合物
CN103597646A (zh) 2011-05-31 2014-02-19 默克专利股份有限公司 电解质组合物
WO2014004676A1 (fr) 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Utilisation des inhibiteurs de faah comme agents neuroprotecteurs du snc
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
WO2014207100A1 (fr) 2013-06-27 2014-12-31 Basf Se Procédé de couchage du papier à la cellulose à l'aide d'une solution contenant de la cellulose
JP6026024B2 (ja) 2013-06-27 2016-11-16 ファイザー・インク 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
US20170015871A1 (en) 2013-11-29 2017-01-19 Proionic Gmbh Method for curing an adhesive using microwave irradiation
WO2015184011A2 (fr) * 2014-05-28 2015-12-03 Sanford-Burnham Medical Research Institute Agonistes du récepteur de l'apéline et leurs procédés d'utilisation
CN106459004B (zh) * 2014-06-06 2020-09-15 研究三角协会 爱帕琳肽受体(apj)激动剂及其用途
WO2016074757A1 (fr) 2014-11-11 2016-05-19 Merck Patent Gmbh Procédé de production des sels de mono(perfluoroalkyl)fluorophosphate et de bis(perfluoroalkyl)fluorophosphate et leurs acides
JP6358639B2 (ja) 2015-04-24 2018-07-18 塩野義製薬株式会社 ６員複素環誘導体およびそれらを含有する医薬組成物
CA2985542C (fr) 2015-05-20 2023-10-10 Amgen Inc. Triazoles agonistes du recepteur apj
RS59220B1 (sr) * 2015-06-03 2019-10-31 Bristol Myers Squibb Co 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primenu u lečenju kardiovaskularnih poremećaja
KR101711744B1 (ko) 2015-07-16 2017-03-02 경희대학교 산학협력단 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층
SG10201908839QA (en) 2015-10-14 2019-10-30 Bristol Myers Squibb Co 2,4-dihydroxy-nicotinamides as apj agonists
WO2017091513A1 (fr) 2015-11-24 2017-06-01 Daiichi Sankyo Company, Limited Nouveaux dérivés azolés comme agoniste du récepteur de l'apéline
KR102678264B1 (ko) 2015-12-04 2024-06-24 브리스톨-마이어스 스큅 컴퍼니 아펠린 수용체 효능제 및 사용 방법
JP6948322B2 (ja) 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン
JP6716711B2 (ja) * 2016-03-24 2020-07-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊアゴニストとしての６−ヒドロキシ−４−オキソ−１，４−ジヒドロピリミジン−５−カルボキシアミド
EP3468952B1 (fr) 2016-06-14 2020-11-25 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones utilisés en tant qu'agonistes du récepteur apj
KR102384668B1 (ko) 2016-06-14 2022-04-07 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온

Also Published As

Publication number Publication date
SG11201808163WA (en) 2018-10-30
IL261904A (en) 2018-10-31
ES2895124T3 (es) 2022-02-17
US10106528B2 (en) 2018-10-23
EP3433247A1 (fr) 2019-01-30
TWI744301B (zh) 2021-11-01
US20190002441A1 (en) 2019-01-03
JP2019509319A (ja) 2019-04-04
UY37169A (es) 2017-09-29
KR102433280B1 (ko) 2022-08-17
US20170275272A1 (en) 2017-09-28
AR107973A1 (es) 2018-07-04
BR112018068341A2 (pt) 2019-01-15
CA3018346A1 (fr) 2017-09-28
WO2017165640A1 (fr) 2017-09-28
AU2017238504A1 (en) 2018-11-15
EA037162B1 (ru) 2021-02-12
TW201736362A (zh) 2017-10-16
IL261904B (en) 2020-09-30
ZA201806356B (en) 2021-05-26
CL2018002671A1 (es) 2019-01-25
AU2017238504B2 (en) 2021-05-27
MX2018011194A (es) 2019-01-10
CN109195963A (zh) 2019-01-11
JP6716711B2 (ja) 2020-07-01
MY189454A (en) 2022-02-14
CO2018011105A2 (es) 2018-10-22
CN109195963B (zh) 2021-04-23
EA201892123A1 (ru) 2019-02-28
EP3433247B1 (fr) 2021-09-08
KR20180129836A (ko) 2018-12-05
MX379088B (es) 2025-03-10
US10590113B2 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
MA43761A (fr) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
LT3580220T (lt) Aminotriazolopiridinai, kaip kinazės inhibitoriai
LT3303334T (lt) Tirozinkinazės inhibitoriai
LT3105226T (lt) Ciklopropilaminai, kaip lsd1 inhibitoriai
BR112017004334A2 (pt) inibidores de desmetilase específica de lisina-1.
MA42242A (fr) Inhibiteurs de la tyrosine kinase
MA44474A (fr) Nouveaux inhibiteurs de la ferroportine
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
MA53944A (fr) Inhibiteurs de la glycosidase
EP3313828A4 (fr) Inhibiteurs de métallo-bêta-lactamases
HUE054784T2 (hu) 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
MA49639A (fr) Polymorphes de 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
LT3704118T (lt) Aminoimidazopiridazinai, kaip kinazės inhibitoriai
EP3713931C0 (fr) 3-oxo-6-hétéroaryl-2-phényl-2,3-dihydropyridazine-4-carboxamides
MA42597A (fr) 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
LT3288944T (lt) Imidazopirazinonai, kaip pde1 inhibitoriai
DK3341379T3 (da) EZH2-hæmmere
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
FR3025204B1 (fr) Copolymeres a blocs utilisables comme fluidifiants
BR112017022691A2 (pt) inibidor de bromodomínio.